eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 12
Original paper

Twelve months clinical outcome after bioresorbable vascular scaffold implantation in patients with stable angina and acute coronary syndrome. Data from the Polish National Registry

Łukasz Rzeszutko, Zbigniew Siudak, Tomasz Tokarek, Krzysztof Plens, Adrian Włodarczak, Andrzej Lekston, Andrzej Ochała, Robert J. Gil, Wojciech Balak, Dariusz Dudek

Adv Interv Cardiol 2016; 12, 2 (44): 108–115
Online publish date: 2016/05/11
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Introduction: There are limited data describing bioresorbable vascular scaffold (BVS) implantation in complex lesions. Only short-term clinical outcomes are available for patients with acute coronary syndrome (ACS).

Aim: To evaluate 12-month clinical outcome, safety and effectiveness of BVS implantation in complex lesions and in stable angina (SA) or ACS.

Material and methods: Five hundred ninety-one patients with SA/ACS were enrolled between October 2012 and November 2013 in 30 invasive cardiology centres in Poland. At least one BVS implantation during percutaneous coronary intervention (PCI) was the only inclusion criteria. The clinical endpoint was the occurrence of a major adverse cardiovascular event (MACE) (all-cause death, myocardial infarction (MI), clinically driven target lesion revascularisation (TLR) with urgent PCI or target vessel revascularisation (TVR) with urgent coronary artery bypass grafting (CABG)) and device-oriented composite endpoint (DOCE) (cardiac death, urgent target vessel revascularisation with PCI/CABG, target vessel MI) during 12-month follow-up.

Results: After 12 months TLR with urgent PCI was significantly more often reported in patients with diagnosed UA (4.59%; p < 0.02) in comparison with other PCI indications. No significant differences were found in terms of composite MACE endpoint, cumulative MACE (p = 0.09), stent thrombosis (p = 0.2) or restenosis (p = 0.2). There were no significant differences in cumulative MACE and composite MACE endpoint between patients with no/mild versus moderate/severe tortuosity and no/mild versus moderate/severe calcification of the target vessel. No significant difference was found between groups of patients with or without bifurcation of the target vessel. Device-oriented composite endpoint was significantly more often reported in the ACS group (3.2% vs. 0.47%; p < 0.03), most frequently in patients with diagnosed UA (5.5%).

Conclusions: Bioresorbable vascular scaffold can be successfully and safely used for ACS treatment and in lesions of higher complexity.

stent, calcified, bifurcation, tortuosity, complex lesion

Karabulut A, Demirci Y. Cutting balloon use may ease the optimal apposition of bioresorbable vascular scaffold in in-stent stenosis. Postep Kardiol Inter 2015; 11: 64-6.
Rama-Merchan JC, Mattesini A, Dall’Ara G, et al. Chronic total occlusion successfully treated with a bioresorbable everolimus-eluting vascular scaffold. Postep Kardiol Inter 2014; 10: 128-39.
Onuma Y, Serruys PW, Perkins LEL, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary arterymodel: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010; 122: 2288-300.
Bruining N, de Winter S, Roelandt JRTC, et al. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. JACC Cardiovasc Interv 2010; 3: 449-56.
Lesiak M, Araszkiewicz A. Leaving nothing behind: is the bioresorbable vascular scaffold a new hope for patients with coronary artery disease? Postep Kardiol Inter 2014; 10: 283-98.
Dariusz Dudek D, Rzeszutko Ł, Zasada W, et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol Arch Med Wewn 2014; 124: 669-77.
Cortese B, Ielasi A, Varricchio A, et al. Registro Absorb Italiano (BVS-RAI): an investigators-owned and -directed, open, prospective registry of consecutive patients treated with the Absorb™ BVS: study design. Cardiovasc Revasc Med 2015; 16: 340-3.
Gori T, Schulz E, Hink U, et al. Clinical, angiographic, functional, and imaging outcomes 12 months after implantation of drug-eluting bioresorbable vascular scaffolds in acute coronary syndromes. JACC Cardiovasc Interv 2015; 8: 770-7.
Rzeszutko Ł, Siudak Z, Włodarczak A, et al. Use of bioresorbable vascular scaffolds in patients with stable angina and acute coronary syndromes. Polish National Registry. Kardiol Pol 2014; 72: 1394-409.
Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-351.
Giuseppe G, Ortega-Paz L, Brugaletta S, et al. Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks. Postep Kardiol Inter 2015; 11: 161-9.
Ishibashi Y, Nakatani S, Sotomi Y et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv 2015; 8: 1715-26.
Wöhrle J, Naber C, Schmitz T, et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 2015; 11: 149-56.
Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015; 10: 1144-53.
Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet 2016; 387: 537-44.
Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 2015; 36: 3332-42.
Sabaté M, Windecker S, Iñiguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J 2016; 37: 229-40.
Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (Bioresorbable Vascular Scaffold-A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction). JACC Cardiovasc Interv 2015; 8: 189-97.
Abizaid A, Costa Jr. JR, Bartorelli AL, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. Euro Intervention 2015; 10: 1396-401.
Costopoulos C, Latib A, Naganuma T, et al. Comparison of early clinical outcomes between Absorb bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc Interv 2015; 1: E10-5.
Mattesini A, Secco GG, Dall’Ara G, et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv 2014; 7: 741-50.
Caiazzo G, Kilic ID, Fabris E, et al. Absorb bioresorbable vascular scaffold: what have we learned after 5 years of clinical experience? Int J Cardiol 2015; 15: 129-36.
Jaguszewski M, Ghadri JR, Zipponi M, et al. Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios. Clin Res Cardiol 2015; 2: 124-35.
Robaei D, Back LM, Ooi SY, et al. Everolimus-eluting bioresorbable vascular scaffold implantation in real world and complex coronary disease: procedural and 30-day outcomes at two Australian centres. Heart Lung Circ 2015; 9: 854-9.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe